key: cord-0848503-5ncazcwd
authors: Marcotte, Harold; Piralla, Antonio; Zuo, Fanglei; Du, Likun; Cassaniti, Irene; Wan, Hui; Kumagai-Braesh, Makiko; Andréll, Juni; Percivalle, Elena; Sammartino, Josè Camilla; Wang, Yating; Vlachiotis, Stelios; Attevall, Janine; Bergami, Federica; Ferrari, Alessandro; Colaneri, Marta; Vecchia, Marco; Sambo, Margherita; Zuccaro, Valentina; Asperges, Erika; Bruno, Raffaele; Oggionni, Tiberio; Meloni, Federica; Abolhassani, Hassan; Bertoglio, Federico; Schubert, Maren; Calzolai, Luigi; Varani, Luca; Hust, Michael; Xue, Yintong; Hammarström, Lennart; Baldanti, Fausto; Pan-Hammarström, Qiang
title: Immunity to SARS-CoV-2 up to 15 months after infection
date: 2022-01-07
journal: iScience
DOI: 10.1016/j.isci.2022.103743
sha: ae6f4e4a458749d3d94d4d97e4f096c89c0dcc86
doc_id: 848503
cord_uid: 5ncazcwd

Information concerning the longevity of immunity to SARS-CoV-2 following natural infection may have considerable implications for durability of immunity induced by vaccines. Here, we monitored the SARS-CoV-2 specific immune response in COVID-19 patients followed up to 15 months after symptoms onset. Following a peak at day 15-28 post-infection, the IgG antibody response and plasma neutralizing titers gradually decreased over time but stabilized after 6 months. Compared to G614, plasma neutralizing titers were more than 8-fold lower against variants Beta, Gamma and Delta. SARS-CoV-2-specific memory B and T cells persisted in the majority of patients up to 15 months although a significant decrease in specific T cells, but not B cells, was observed between 6 and 15 months. The antiviral specific immunity especially memory B cells in COVID-19 convalescent patients is long-lasting, but some variants of concern may at least partially escape the neutralizing activity of plasma antibodies.

Coronavirus disease 2019 , caused by the novel severe acute respiratory 52 syndrome coronavirus 2 (SARS-CoV-2), rapidly resulted in a pandemic constituting a global 53 health emergency. The COVID-19 pathological process exhibits a wide spectrum of clinical 54 manifestations, ranging from asymptomatic to mild, moderate, severe and critical disease. The 55 genome of SARS-CoV-2 encodes four major structural proteins that occur in all 56 coronavirus species: spike protein (S), nucleoprotein (N), membrane protein (M), and 57 envelope protein (E) (Naqvi et al., 2020) . The S protein binds to the host receptor 58

(Angiotensin Converting Enzyme 2 [ACE2]) through the receptor-binding domain (RBD) in the 59 S1 subunit, followed by the S2 subunit-mediated cell membrane fusion (Zhou et al., 2020) . 60

The adaptive immune response is likely to be critical for the development of protective 62 immunity to SARS-CoV-2 including viral clearance and the persistence of antiviral immunity 63 (Poland et al., 2020) . Generation of neutralizing antibodies that specifically target the receptor-64 binding domain (RBD) of the S protein is considered to be essential in controlling SARS-CoV- The neutralizing activity against the G614 variant was measured by a microneutralization 161 assay and was expressed as the neutralizing titers (≥ 1:10) which inhibit 90% of the virus 162 infectivity (NT90). Similar to the dynamic of the anti-RBD and anti-S antibodies, the median 163 NT90 reached a peak of 1:160 between 15-28 days with 98% (51/52) of convalescent patients 164 exhibiting plasma neutralizing activity ( Figures 4A and 4B ). The plasma NT90 gradually 165 decreased by about 2-fold up to 6 months (15-28 vs 91-180 days, p = 0.0493) but was still 166 observed in more than 87% (35/40) of the patients sampled at 181-365 (27/31) and 366-452 167 days (8/9) ( Figure 4B ). Furthermore, no significant difference was observed in the median NT90 168 measured at 181-365 (1:40) and 366-452 days (1:80) (p = 0.6674; Figure 4B ) or between 169 paired samples at two time points between 6 and 15 months (n = 9, TP1: 181-300 days vs 170 TP2: 301-452 days, p = 0.5156; Figure 4C ). A one-phase decay model showed a rapid initial 171 decay using both cross-sectional (t1/2 = 70 days, Figure 4A ) or longitudinal analysis (t1/2 = 44 172 days, Figure 4C ) which slow down to a plateau phase extending from around 4 up to 15 173 months. A decrease of NT90 followed by a plateau phase was observed in both patients with 174 mild/moderate and severe/critical diseases using cross-sectional analysis ( Figure S1C ) while 175 no decline was observed for the severe/critical patients group using longitudinal analysis 176 ( Figure S1F ) suggesting that neutralization activity may persist longer in this group. The NT90 177 directly correlated (p < 0.0001) with the levels of RBD-specific IgM (r = 0.45), IgA (r = 0.37) 178

and IgG (r = 0.49) as well as with the level of S-specific IgM (r = 0.44), IgA (r = 0.44) and IgG 179 (r = 0.55) antibodies ( Figure S2 ). 180

In order to evaluate if the convalescent patients could be protected from the circulating VOCs, 182 we determined the cross-binding and cross-neutralizing activity against Alpha, Gamma, Beta 183 and Delta variants using plasma collected at the early (15-106 days, median day of 24) and 184 late (259-452 days, median day of 370) phase of convalescence from February to May 2021. 185

As described earlier, the IgG anti-RBD titers against wild-type RBD were higher in early ( Figure  186 4D) compared to late convalescence ( Figure 4G ). Furthermore, a reduction in the level of IgG 187 antibodies binding to Gamma and Beta RBD was observed using both plasma samples 188 J o u r n a l P r e -p r o o f detected in the negative controls. Overall, a T cell response against at least one of the SARS-245

CoV-2 peptide pools (S1, or S N M O protein derived) was detectable at a level above the 246 cutoff in 95% (69/73) of the patient samples tested over the study period ( Figures 6A-6C and 247 S4A-S4C). When divided by groups based on the sample time points, specific T cells were 248 detected in the majority of patient samples at 2-4 weeks (10/11, 91%) and 1-3 months (7/9, 249 78%), and more than 98% (52/53) of patient samples tested between 3 and 15 months. 250 251 Using cross-sectional analysis, the number of S1-specific IL-2, IFN-γ, and IL-2/IFN-γ-252 producing T cells reached a peak between 3 and 6 months and was maintained up to 15 253 months except for IL-2/IFN-γ-producing T cells which significantly decreased at 366-452 days 254 (vs 181-365 days, p = 0.0215; Figures 6D-6F ). We further analyzed the results using 255 longitudinal data and observed a significant decrease of S1-specific T cells producing IL-2, 256 IFN-γ, and IL-2/IFN-γ between TP1 (180-300 days) and TP2 (301-452 days) (n = 8; p= 0.0156 257 for each of the three cell populations; Figures 6G-6I) . We similarly detected a peak of S N M 258 O pool-specific IL-2, IFN-γ, and IL-2/IFN-γ-producing T cells between 3 and 6 months and a 259 significant decrease of those T cell populations at 12-15 months using both cross-sectional 260 The numbers of S1 and S N M O peptide pool-specific IL2 and IL-2/IFN-γ -producing T cells 265

were higher in severe/critical COVID-19 than mild/moderate patients between 6 and 15 months 266 (p = 0.0044 and p = 0.0202 for S1 specific T cells, p = 0.0302 and p = 0.0427 for S N M O 267 specific T cells) while no significant difference in S1 and S N M O specific IFN-γ -producing T 268 cells was observed (p = 0.0610 and p = 0.1012, respectively) ( Figures S5 and S6) . 269

The S1-specific T cell response measured in samples collected after one vaccine dose was 271 equivalent to that observed in convalescent patients at 12-15 months when the specific T cell 272 number decrease (p = 0.6333, p = 0.8352, p = 0.6893; Figures 6D-6F ). Compared to the peak 273 of T cell response in patients (3-6 months), individuals with two doses of vaccine present a 274 similar level of S1-specific IL-2 and IL-2/IFN-γ-producing T cells but a 2-fold higher number of 275 IFN-γ-producing T cells (p = 0.5177, p = 0.9915, and p = 0.0475, respectively; Figures 6D-6F) . 276 277 Finally, we have investigated the presence of all three arms of immunity for each individual 278 who has been evaluated for SARS-CoV-2-specific adaptive immunity in all assays i.e., 1) IgM, 279

IgG and IgA antibody response and/or neutralization activity, 2) RBD-specific IgG-producing B The magnitude, duration and quality of immunological memory are crucial for preventing 298 reinfection. In this study, we extended our assessment of the longevity of the SARS-CoV-2-299 specific antibody, B and T cell immune response in cohorts of convalescent patients in Italy 300 and Sweden that experienced mild to critical symptoms of COVID-19. In many viral infections, 301 such as those caused by Dengue and Zika virus, serum IgM responses precede the 302 appearance of IgG and IgA antibodies (Roltgen and Boyd, 2021) . In contrast, IgG antibodies 303 to SARS-CoV-2 S and RBD appear at approximately the same time as serum IgM and IgA 304 antibodies, usually within the first 2 weeks after symptom onset which might be due to a longer 305 asymptomatic period. In accordance with previous studies, although the RBD-and S-specific 306

IgG titers peaked 14-30 days after infection and gradually decreased over time, the IgG 307 antibody response stabilized after 6 months and was still detected in the majority of 308 (Table S3) . 465

responses although we also made a comparison between mild/moderate and severe/critical 467 patients (Fig. S2) . Furthermore, although based on available clinical data, no evidence 468 suggests reinfection in any of the donors tested, the long duration of the immune response, 469 including the increase in neutralization activity in some recovered participants, could 470 theoretically be related to a natural boost after a re-exposure to the virus. We thank all the patients, blood donors, clinicians and nurses for their contributions. This 14.81 AU/mL for IgG, respectively, giving a specificity of 96% for IgM, 99% for IgA and 97% 527 IgG). The cutoff-value is not visible in some graphs because it is very close to the X-axis. 528

Mann-Whitney U test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p < 0.0001. 529

See also Figures S1 and S2 . for IgA, and 0.03 and 14.81 AU/mL for IgG, respectively, giving a specificity of 96% for IgM, 541 99% for IgA and 97% IgG). The cutoff-value is not visible in some graphs because it is very 542 close to the X-axis. Wilcoxon signed-rank test. 543

See also Figure S1 . number of specific T cell spots for the negative controls (> 7 to 9 spots / 300 000 seeded cells 601

depending on the T cell population). The cutoff-value is not visible in some graphs because it 602 is very close to the X-axis. Mann-Whitney U test. **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001. 603

See also Figures S4-S6 . The article includes all datasets generated or analyzed during this study. 631  Data reported in this paper will be shared by the lead contact upon reasonable request. Table S1 and summarized in Table S2 and 16 were sampled either after the first (n=8) or second (n=8) dose for a total of 15 samples 687 after each dose (Figure 1, Table S4 ). 

RBD IgM, IgA, IgG) in 0.1% BSA in PBS, was incubated for 1.5 h at room temperature. Plates 710 were then washed and incubated for 1h at room temperature with horseradish peroxidase 711 (HRP)-conjugated goat anti-human IgM (Invitrogen #A18835), goat anti-human IgA

or goat anti-human IgG (Invitrogen #A18805)

Bound antibodies were detected using tetramethylbenzidine substrate

The color reaction was stopped with 0.5M H2SO4 and absorbance was measured at 715

AU/ml), based on a standard curve 716 made from a serially diluted highly positive serum pool. In-house standards made by pooled 717 highly positive serum were calibrated by using the WHO International Standard for

CoV-2 immunoglobulin (NIBSC, 20/136). 1 AU/ml of in-house serum standard equal to 30

59 BAU/ml IgA and 4.10 BAU/ml IgG of the WHO international standards

Cutoff values for antibody positivity were determined based on receiver operating 721 characteristic curves with data from convalescent COVID-19 patients and negative historical 722 control samples. The cutoff value for positivity was set at > 2.5 AU/ml for anti-S IgM

03 AU/ml for anti-S IgG, > 8.4 AU/ml for anti-RBD IgM, > 0.08 AU/ml 724 for anti-RBD IgA, and > 14.8 AU/ml for anti-RBD IgG, giving a specificity of 96% for IgM

For assessing the anti-RBD IgG binding activity against VOCs, plates were coated with RBD 728 derived from Alpha, Beta, Gamma, and Delta (1.7 μg/ml) and 1:1600 dilution of selected serum 729 or plasma collected from

Horseradish 731 peroxidase (HRP)-conjugated goat anti-human IgG and tetramethylbenzidine substrate were 732 added as described above and the color reaction was stopped with 0.5M H2SO4 after 10 min 733 incubation

and 765 recombinant human IL-2 (10 ng/ml) for stimulation of memory B cells. The ELISpot plates pre-766 coated with capturing monoclonal anti-human IgG antibodies were incubated with a total of 767 300 000 or 30 000 viable pre-stimulated cells per well for detection of RBD-specific IgG

total IgG (positive control) secreting cells, respectively. The number of B cells secreting SARS-769

CoV-2 RBD-specific IgG and total IgG were measured using the Human IgG SARS-CoV-2

O specific IFN-γ and IL-2-secreting T cells were detected using the Human

The plates pre-774 coated with capturing monoclonal anti-IFN- and anti-IL-2 were incubated overnight in RPMI-775 1640 medium containing 10% FCS

A polyclonal activator for human T cells (anti-778 human CD3 monoclonal antibody CD3-2, #3605-1, Mabtech) was used as a positive control 779 for cytokine secretion. The SARS-CoV-2 S1 scanning pool contains 166 peptides from the 780 human SARS-CoV-2 virus (#3629-1, Mabtech AB). The peptides are 15-mers overlapping with 781 11 amino acids

O defined peptide pool contains 47 synthetic peptides binding to human HLA

S2 N defined peptide pool contains 41 synthetic peptides binding to human HLA 785 derived from the S and N proteins of the SARS-CoV-2 virus (#3620-1

Results of ELISpot and FluoroSpot assays were evaluated using an IRIS-reader and analyzed 789 by the IRIS software version 1.1.9 (Mabtech AB). The results were expressed as the number 790 of spots per 300 000 seeded cells after subtracting the background spots of the negative 791 References responses and duration of immunity: a longitudinal study

Longitudinal analysis shows durable and 866 broad immune memory after SARS-CoV-2 infection with persisting antibody responses 867 and memory B and T cells

Detection of 2019 novel 870 coronavirus (2019-nCoV) by real-time RT-PCR

Cutting 873 edge: long-term B cell memory in humans after smallpox vaccination

Immunological memory to SARS-CoV-2 assessed for 877 up to 8 months after infection

Estimated 880 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Increased mortality in community-tested cases of SARS-CoV-2 884 lineage B.1.1.7

Genomic characterization and epidemiology 887 of an emerging SARS-CoV-2 variant in Delhi

Emergence and spread of SARS-CoV-2 lineages 891 B.1.1.7 and P.1 in Italy

Infection-and vaccine-induced 894 antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Seasonal coronavirus protective 898 immunity is short-lasting

Distinct antibody and memory B cell 901 responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination

Targets of T cell responses 905 to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed 906 individuals

Long-term 908 persistence of IgG antibodies in SARS-CoV infected healthcare workers

Duration of antiviral immunity after smallpox vaccination

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-915 tested individuals in Denmark in 2020: a population-level observational study

Rapid generation of durable B cell 919 memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and 920 convalescence

Association of SARS-CoV-2 923 seropositive antibody test with risk of future infection

A systematic 927 review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, 928 and association with severity

Rapid decay of anti-931 SARS-CoV-2 antibodies in persons with mild Covid-19

Personalized Virology Initiative study

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Neutralizing antibody levels are 939 highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Baculovirus-free insect cell 943 expression system for high yield antibody and antigen production

SARS-CoV-2-specific T cell immunity in cases of 947 COVID-19 and SARS, and uninfected controls

Identification of SARS-CoV-2 951 spike mutations that attenuate monoclonal and serum antibody neutralization

Antibody status and incidence 955 of SARS-CoV-2 infection in health care workers

Delta variant: What is happening with transmission, hospital admissions, 958 and restrictions?

Insights into SARS-CoV

genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

HIV+ elite 965 controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell 966 responses

Broad and strong memory CD4(+) and CD8(+) T cells 969 induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Prevalence of SARS-CoV-2 specific 973 neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 974 06

Reduced sensitivity of 977 SARS-CoV-2 variant Delta to antibody neutralization

SARS-CoV-2 immunity: review 980 and applications to phase 3 vaccine candidates

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

SARS-CoV-2 B.1.1.7 987 and B.1.351 spike variants bind human ACE2 with increased affinity

Functional 991 SARS-CoV-2-specific immune memory persists after mild COVID-19

Antibody and B cell responses to SARS-CoV-2 infection 994 and vaccination

Defining the features and duration of 997 antibody responses to SARS-CoV-2 infection associated with disease severity and 998 outcome

Antigen-specific adaptive 1001 immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease 1002 severity

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

SARS-CoV-2-specific T cell responses 1009 and correlations with COVID-19 patient predisposition

Robust T Cell 1013 immunity in convalescent individuals with asymptomatic or mild COVID-19

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, 1017 and vaccine effectiveness

Persistence of SARS-CoV-2-1020 specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the 1021 infection

Complete map of SARS-1023

CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail 1024 with LY-CoV016

Early induction of functional SARS-CoV-2-1027 specific T cells associates with rapid viral clearance and mild disease in COVID-19 1028 patients

The biological and clinical significance of emerging SARS-CoV-1031 2 variants

SARS-CoV-2 infection induces long-lived 1034 bone marrow plasma cells in humans

Robust neutralizing antibodies to 1038 SARS-CoV-2 infection persist for months

Susceptibility of circulating SARS-CoV-2 variants to 1042 neutralization

Increased resistance of SARS-CoV-2 variant P.1 to 1045 antibody neutralization

Naturally enhanced neutralizing 1049 breadth against SARS-CoV-2 one year after infection

Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent 1053 COVID-19 patients one year post symptom onset

A pneumonia outbreak associated with a new coronavirus of probable 1057 bat origin